Neoprobe Corporation (NEOP.OB), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, reports positive preliminary results from a multicenter Phase 2 clinical study of its lead clinical candidate, Lymphoseek®. (Technetium Tc99m DTPA-mannosyl-dextran).
Lymphoseek is a proprietary radioactive targeting agent being developed for use with handheld gamma detection devices, such as Neoprobe’s neo2000® system, in a surgical procedure known as Sentinel Lymph Node Biopsy (SLNB).
The primary endpoint of this multicenter, single-arm, open-label, within-patient, single-dose, multi-stage trial measured the rate at which Lymphoseek localized to lymphoid tissue with a goal of achieving 90% localization.
In results reported today, localization of Lymphoseek to lymphoid tissue was observed in over 94% of the SLNB procedures performed as a part of the Phase 2 trial in patients with either breast cancer or melanoma.
Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients.
Neoprobe currently markets the neo2000® line of gamma detection systems that are widely used by cancer surgeons and is commercializing the Quantix® line of blood flow measurement products developed by its subsidiary, Cardiosonix Ltd.
In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek® and RIGScan® CR.
Let us hear your thoughts below: